UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Form 10-Q
(Mark One)
(X)
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2004
or
( )
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number: 000-27765
SYMYX TECHNOLOGIES, INC.
| Delaware | 77-0397908 | |
| (State or other jurisdiction of | (I.R.S. Employer | |
| incorporation or organization) | Identification No.) | |
| 3100 Central Expressway, | ||
| Santa Clara, California | 95051 | |
| (Address of principal executive offices) | (Zip Code) |
(408) 764-2000
(Registrants telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports) and, (2) has been subject to such
filing requirements for the past 90 days.
Yes ý No o
Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act).
Yes ý No o
As of October 29, 2004, Registrant had outstanding 32,161,515 shares of Common Stock, $.001 par value.
TABLE OF CONTENTS
| PAGE |
||||||||
| Part I: Financial Information | ||||||||
| Financial Statements: | ||||||||
| 1 | ||||||||
| 2 | ||||||||
| 3 | ||||||||
| 4 | ||||||||
| 15 | ||||||||
| 34 | ||||||||
| Controls and Procedures | 34 | |||||||
| Part II: Other Information | ||||||||
| Legal Proceedings | 35 | |||||||
| 35 | ||||||||
| Defaults Upon Senior Securities | 35 | |||||||
| 35 | ||||||||
| Other Information | 35 | |||||||
| Exhibits | 35 | |||||||
| Signatures | 36 | |||||||
| Exhibit Index | 37 | |||||||
| EXHIBIT 31.1 | ||||||||
| EXHIBIT 31.2 | ||||||||
| EXHIBIT 32.1 | ||||||||
PART I: FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
SYMYX TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, |
September 30, |
|||||||||||||||
| 2004 |
2003 |
2004 |
2003 |
|||||||||||||
Revenue: |
||||||||||||||||
Service revenue from research collaborations |
$ | 10,299 | $ | 9,979 | $ | 30,789 | $ | 27,077 | ||||||||
Service
revenue - related party |
7 | 595 | 1,168 | 1,030 | ||||||||||||
Product sales |
5,120 | 959 | 15,484 | 9,586 | ||||||||||||
License fees and royalties |
4,132 | 2,936 | 10,512 | 6,632 | ||||||||||||
Total revenue |
19,558 | 14,469 | 57,953 | 44,325 | ||||||||||||
Operating expenses: |
||||||||||||||||
Cost of products sold |
1,437 | 154 | 5,055 | 2,032 | ||||||||||||
Research and development |
9,857 | 9,816 | 29,960 | 28,909 | ||||||||||||
Research and
development - related party |
7 | 595 | 1,168 | 1,030 | ||||||||||||
Sales, general and administrative |
4,375 | 3,485 | 12,797 | 10,856 | ||||||||||||
Total operating expenses |
15,676 | 14,050 | 48,980 | 42,827 | ||||||||||||
Income from operations |
3,882 | 419 | 8,973 | 1,498 | ||||||||||||
Interest and other income (expense), net |
610 | 439 | 1,845 | 1,506 | ||||||||||||
Income before income tax expense |
4,492 | 858 | 10,818 | 3,004 | ||||||||||||
Income tax expense |
1,720 | 206 | 4,327 | 1,021 | ||||||||||||
Net income |
$ | 2,772 | $ | 652 | $ | 6,491 | $ | 1,983 | ||||||||
Basic net income per share |
$ | 0.09 | $ | 0.02 | $ | 0.20 | $ | 0.06 | ||||||||
Diluted net income per share |
$ | 0.08 | $ | 0.02 | $ | 0.19 | $ | 0.06 | ||||||||
Shares used in computing basic net income per share |
32,118 | 31,303 | 31,985 | 31,082 | ||||||||||||
Shares used in computing diluted net income per share |
33,428 | 33,065 | 33,719 | 32,264 | ||||||||||||
See accompanying notes to condensed consolidated financial statements
1
SYMYX TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
| September 30, | December 31, | |||||||
| 2004 |
2003 |
|||||||
| (Unaudited) | (Note 1) | |||||||
ASSETS |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 14,199 | $ | 17,110 | ||||
Available-for-sale securities |
138,648 | 121,588 | ||||||
Accounts receivable |
5,023 | 2,617 | ||||||
Inventories |
3,182 | 3,743 | ||||||
Receivable from related party |
7 | | ||||||
Interest receivable and other current assets |
3,615 | 4,194 | ||||||
Total current assets |
164,674 | 149,252 | ||||||
Property, plant and equipment, net |
23,234 | 25,681 | ||||||
Deferred tax assets and other assets |
2,431 | 2,603 | ||||||
Total assets |
$ | 190,339 | $ | 177,536 | ||||
LIABILITIES AND STOCKHOLDERS EQUITY |
||||||||
Current liabilities: |
||||||||
Accounts payable and other accrued liabilities |
$ | 4,224 | $ | 4,643 | ||||
Accrued compensation and employee benefits |
3,232 | 2,142 | ||||||
Advance from related party |
| 137 | ||||||
Income taxes payable |
5,611 | 1,055 | ||||||
Deferred rent |
741 | 681 | ||||||
Deferred revenue |
2,208 | 7,640 | ||||||
Warranty expense accrual |
1,535 | 1,800 | ||||||
Total current liabilities |
17,551 | 18,098 | ||||||
Commitments |
||||||||
Stockholders equity: |
||||||||
Preferred stock, $0.001 par value, 10,000,000
shares authorized, issuable in series; no
shares issued and outstanding |
| | ||||||
Common stock, $0.001 par value, 60,000,000
shares authorized and 32,144,960 and
31,610,108 shares issued and outstanding at
September 30, 2004 and December 31, 2003,
respectively |
32 | 32 | ||||||
Additional paid-in capital |
169,266 | 162,160 | ||||||
Stockholder notes receivable |
| (134 | ) | |||||
Deferred stock compensation |
| (7 | ) | |||||
Accumulated other comprehensive income (loss) |
(357 | ) | 31 | |||||
Retained earnings (accumulated deficit) |
3,847 | (2,644 | ) | |||||
Total stockholders equity |
172,788 | 159,438 | ||||||
Total liabilities and stockholders equity |
$ | 190,339 | $ | 177,536 | ||||
See accompanying notes to condensed consolidated financial statements
2
SYMYX TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Nine Months Ended | ||||||||
| September 30, |
||||||||
| 2004 |
2003 |
|||||||
Operating activities |
||||||||
Net income |
$ | 6,491 | $ | 1,983 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
Depreciation and amortization |
9,900 | 8,821 | ||||||
Stock-based compensation |
150 | 38 | ||||||
Deferred tax benefit |
| 24 | ||||||
Gain on sale of fixed assets |
(156 | ) | | |||||
Changes in assets and liabilities: |
||||||||
Accounts receivable |
(2,406 | ) | 6,179 | |||||
Inventories |
561 | (1,374 | ) | |||||
Receivable from related party |
(7 | ) | | |||||
Interest receivable and other current assets |
851 | (241 | ) | |||||
Other long-term assets |
36 | 112 | ||||||
Accounts payable and other accrued liabilities |
(419 | ) | 1,020 | |||||
Accrued compensation and employee benefits |
1,090 | 323 | ||||||
Advance from related party |
(137 | ) | | |||||
Income taxes payable |
4,312 | 1,420 | ||||||
Deferred rent |
60 | 97 | ||||||
Deferred revenue |
(5,432 | ) | 270 | |||||
Warranty expense accrual |
(265 | ) | 52 | |||||
Net cash provided by operating activities |
14,629 | 18,724 | ||||||
Investing activities |
||||||||
Purchase of property and equipment, net |
(3,511 | ) | (7,329 | ) | ||||
Purchase of available-for-sale securities |
(85,911 | ) | (97,016 | ) | ||||
Proceeds from maturities of available-for-sale securities |
64,793 | 76,515 | ||||||
Acquisition of technology |
| (65 | ) | |||||
Net cash used in investing activities |
(24,629 | ) | (27,895 | ) | ||||
Financing activities |
6,963 | 5,897 | ||||||
Proceeds from issuance of common stock, net of repurchases |
||||||||
Repayment of shareholder notes receivable |
134 | | ||||||
Net cash provided by financing activities |
7,097 | 5,897 | ||||||
Effect of foreign exchange rate changes on cash and cash equivalents |
(8 | ) | (1 | ) | ||||
Net decrease in cash and cash equivalents |
(2,911 | ) | (3,275 | ) | ||||
Cash and cash equivalents at beginning of period |
17,110 | 25,629 | ||||||
Cash and cash equivalents at end of period |
$ | 14,199 | $ | 22,354 | ||||
Supplemental disclosure of cash flow information |
||||||||
Income taxes paid (refunded) |
$ | 18 | $ | (446 | ) | |||
See accompanying notes to condensed consolidated financial statements
3
SYMYX TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. Summary of Significant Accounting Policies
Business and Basis of Presentation
Symyx Technologies, Inc. (the Company or Symyx) develops and applies high-throughput experimentation for the discovery of innovative materials for chemical and petrochemical, pharmaceutical development, electronics, consumer goods, and automotive customers. Symyx works with companies seeking to transform their search for better products and processes through research collaborations, Discovery Tools® sales, and the license of materials, intellectual property, and software.
Symyx® was incorporated in California on September 20, 1994 and completed a reincorporation in the state of Delaware in February 1999. Symyxs headquarters and mailing address is 3100 Central Expressway, Santa Clara, California, 95051, and the telephone number at that location is (408) 764-2000. Our SEC filings are available free of charge through our website at www.symyx.com. Our common stock trades on the Nasdaq National Market under the symbol SMMX.
The accompanying unaudited condensed consolidated financial information has been prepared by management, in accordance with generally accepted accounting principles for interim financial information and pursuant to instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to the Securities and Exchange Commissions rules and regulations. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position at September 30, 2004 and results of operations and cash flows for all periods presented have been made. The consolidated condensed balance sheet at December 31, 2003 has been derived from the audited financial statements at that date.
These condensed consolidated financial statements should be read in conjunction with the Companys audited financial statements as included in the Companys 2003 Annual Report on Form 10-K as filed with the Securities and Exchange Commission. The results of operations for the three and nine months ended September 30, 2004 are not necessarily indicative of the results to be expected for any subsequent quarter or for the entire fiscal year ending December 31, 2004.
Principles of consolidation
These condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Symyx Technologies AG, incorporated in Switzerland and Symyx Discovery Tools, Inc., incorporated in California. All significant inter-company balances and transactions have been eliminated on consolidation.
Reclassifications
Certain reclassifications have been made to prior period amounts to conform to the current period presentations. Segment revenue for prior periods has been reclassified to conform to the current period presentations. Amounts received from a related party reported as accounts payable and deferred revenue in the previous period have been reclassified as an advance from a related party.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to exercise judgment in making estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from these estimates.
The actual results with regard to warranty expenditures could entail adjustments to be made to the Companys financial statements if system failures or the cost to repair systems differ from what the Company has used in estimating the warranty expense accrual.
4
SYMYX TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Revenue Recognition
The Company generates revenue from services provided under research collaborations, the sale of products, licensing of software, support and maintenance services and the license of intellectual property. It is possible for our customers to work with us in multiple areas of our business and contracts may include multiple elements of service revenue, product revenue and license revenue. In determining the basis for revenue recognition, the Company first determines the fair value of any extended warranty services and defers this revenue to be recognized over the service period. For those contracts that involve multiple element deliverables, the Company identifies all deliverables, determines the units of accounting and allocates revenue between the units of accounting in accordance with the Emerging Issues Task Force consensus on Issue 00-21, Multiple-Deliverable Revenue Arrangements. (EITF 00-21).
Service Revenue
The Company recognizes service revenue from research collaboration agreements and support and maintenance agreements as earned based upon the performance requirements of the agreements. Payments received prior to performance are deferred and recognized as revenue when earned over future performance periods. Collaboration agreements generally specify minimum levels of research effort required to be performed by the Company. Payments received under research collaboration agreements are not refundable if the research is not successful. Direct costs associated with these contracts are reported as research and development expense.
Non-refundable, up-front payments received in connection with research and development collaboration agreements, including technology access fees, are deferred and recognized on a straight-line basis over the relevant periods specified in the agreement (generally the research term). Revenue from milestone payments, which are substantially at risk until the milestones are completed, is recognized upon completion of such milestone events. Because payments under the Companys service agreements are not typically structured with reference to milestones, milestone payments to date have been immaterial.
Product Sales
Product sales revenue includes sales of Discovery Tools hardware and the license of associated software and intellectual property. The Companys Discovery Tools systems are typically delivered under multi-element arrangements, which include hardware, software and intellectual property licenses, and maintenance. A determination is made for each system delivered as to whether software is incidental to the system as a whole. If software is not incidental to the Discovery Tools system as a whole, revenue from these arrangements is recognized in accordance with American Institute of Certified Public Accountants Statement of Position 97-2, Software Revenue Recognition (SOP 97-2), as amended. If software is incidental to the Discovery Tools system, revenue from the sale of the Discovery Tools system is earned and recognized when persuasive evidence of an arrangement exists, delivery of the product has occurred, no significant obligations with regard to implementation remain, the fee is fixed or determinable, and collectibility is probable. This is generally upon shipment, transfer of title to and acceptance by the customer of the hardware and associated software and licenses to intellectual property, unless there are extended payment terms. The Company considers all arrangements with payment terms extending beyond twelve months not to be fixed or determinable. If the fee is not fixed or determinable, revenue is recognized as payments become due from the customer. In multiple element arrangements, the Company uses the residual method to allocate revenue to delivered elements once it has established fair value for all undelivered elements. Payments received in advance under these arrangements are recorded as deferred revenue until earned.
An accrual is established for warranty expenses at the time the associated revenue is recognized. Shipping and insurance costs associated with the sale of discovery tools systems are not material and are included in sales, general and administrative costs.
5
SYMYX TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Software License Fees
Amounts received from third parties for licenses to the Companys software are recognized when earned under the terms of the agreements. For software licensed on an annual right to use basis, the revenue is recognized straight line over the term of the license. For revenue allocable to the software portion of a multiple element arrangement or licensed on a perpetual basis, the Company recognizes revenue upon delivery of the software product to the end-user and commencement of the license, unless the Company has ongoing obligations for which fair value cannot be established or the fee is not fixed or determinable or collectibility is not probable. The Company considers all arrangements with payment terms longer than twelve months not to be fixed or determinable. If the fee is not fixed or determinable, revenue is recognized as payments become due from the customer, provided all the other revenue recognition criteria have been met. In multiple element arrangements, the Company uses the residual method to allocate revenue to delivered elements once it has established fair value for all undelivered elements.
Revenue allocable to support and maintenance is recognized on a straight-line basis over the period the support and maintenance is provided. The Companys product related software licenses may provide for technical support, bug fixes and rights to unspecified upgrades on a when-and-if-available basis for periods defined within the contract. Revenue related to this post-contract customer support is deferred and recognized over the term of the contracted support.
Intellectual Property License Fees
Amounts received from third parties for licenses to the Companys intellectual property are recognized when earned under the terms of the agreements. Generally revenue is recognized upon transfer of the license unless the Company has continuing obligations for which fair value cannot be established, in which case the revenue is recognized over the period of the obligation. If there are extended payment terms, license fee revenue is recognized as these payments become due. The Company considers all arrangements with payment terms extending beyond twelve months not to be fixed or determinable. If there is a provision in the licensing agreement for a variable fee in addition to a non-refundable minimum amount, the amount of the non-refundable minimum guarantee is recognized upon transfer of the license unless the Company has continuing obligations for which fair value cannot be established and the amount of the variable fee in excess of the guaranteed minimum is recognized as revenue when it is fixed and determinable.
Royalties
Royalty revenue is recorded based on reported sales by third-party licensees of products containing the Companys software and intellectual property. If there are extended payment terms, royalty revenues are recognized as these payments become due. Non-refundable royalties, for which there are no further performance obligations, are recognized when due under the terms of the agreements.
Amounts received from third parties for options to license certain technology or enter collaborative arrangements upon specified terms are not recognized as revenue until either the option is exercised or the option right expires.
6
SYMYX TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Concentration of Revenue
For the three and nine months ended September 30, 2004 and 2003, the following customers contributed more than 10% of the Companys total revenue (in thousands):
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, |
September 30, |
|||||||||||||||
| 2004 |
2003 |
2004 |
2003 |
|||||||||||||
ExxonMobil |
$ | 10,687 | $ | 6,409 | $ | 28,975 | $ | 14,241 | ||||||||
Merck |
1,084 | 995 | 3,200 | 5,917 | ||||||||||||
Undisclosed Partner |
250 | 1,955 | 2,083 | 5,538 | ||||||||||||
Total |
$ | 12,021 | $ | 9,359 | $ | 34,258 | $ | 25,696 | ||||||||
The revenue from the above three customers has been included in the following reportable segments for the three and nine months ended September 30, 2004 and 2003 (in thousands):
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, |
September 30, |
|||||||||||||||
| 2004 |
2003 |
2004 |
2003 |
|||||||||||||
Industry Collaborations |
$ | 6,563 | $ | 6,480 | $ | 21,038 | $ | 15,810 | ||||||||
Discovery Tools |
4,708 | 1,629 | 10,970 | 7,886 | ||||||||||||
Intellectual Property Licensing |
750 | 1,250 | 2,250 | 2,000 | ||||||||||||
Total |
$ | 12,021 | $ | 9,359 | $ | 34,258 | $ | 25,696 | ||||||||
The revenue from the above three customers has been included in the Condensed Consolidated Statements of Operations as follows (in thousands):
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, |
September 30, |
|||||||||||||||
| 2004 |
2003 |
2004 |
2003 |
|||||||||||||
Service revenue from
research collaborations |
$ | 5,714 | $ | 5,839 | $ | 19,121 | $ | 15,591 | ||||||||
Product sales |
3,557 | 744 | 6,834 | 4,965 | ||||||||||||
License fees and royalties |
2,750 | 2,776 | 8,303 | 5,140 | ||||||||||||
Total |
$ | 12,021 | $ | 9,359 | $ | 34,258 | $ | 25,696 | ||||||||
7
SYMYX TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Inventories
Work in process inventory consists of customized Discovery Tools systems in the process of being built. Finished goods inventory consists of Discovery Tools systems that have been finished but are pending shipment to customers. Inventories are carried at the lower of cost or market, determined on a specific identification basis. The following table summarizes the components of the Companys inventory balance (in thousands):
| September 30, | December 31, | |||||||
| 2004 |
2003 |
|||||||
Work in Process |
$ | 2,678 | $ | 1,960 | ||||
Finished Goods |
504 | 1,783 | ||||||
Total |
$ | 3,182 | $ | 3,743 | ||||
Warranty expense accrual
The Company offers a warranty on each Discovery Tools System shipped. The specific terms and conditions of these warranties vary depending upon the product sold and country in which the Company does business. However, such warranties typically include coverage for parts and labor and software bug fixes for a specified period (typically one year). The Company estimates the costs that may be incurred under its basic limited warranty and records a liability in the amount of such costs at the time product revenue is recognized. Factors that affect the Companys warranty liability include the number of installed units, historical and anticipated rates of warranty claims, and cost per claim. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts, as necessary.
Changes in the Companys product warranty expense accrual during the nine months ended September 30, 2004 are as follows (in thousands):
Balance as of December 31, 2003 |
$ | 1,800 | ||
New warranties issued during the period |
396 | |||
Costs incurred during the period on specific systems |
(231 | ) | ||
Changes in liability for pre-existing warranties during the
period, including expirations |
(430 | ) | ||
Balance as of September 30, 2004 |
$ | 1,535 | ||
Income Taxes
Income taxes have been provided using the liability method. Deferred tax assets or liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized.
8
SYMYX TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Stock-Based Compensation
Compensation expense for options to purchase the Companys common stock granted to non-employees has been determined in accordance with SFAS 123 and EITF 96-18 as the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Compensation expense for options to purchase the Companys common stock granted to non-employees is periodically re-measured as the underlying options vest.
The Company generally grants stock options to its employees for a fixed number of shares with an exercise price equal to the fair market value of the shares on the date of grant. As allowed under the Statement of Financial Accounting Standards No. 123, Accounting for Stock-Based Compensation (SFAS 123), the Company has elected to follow Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees (APB 25) and related interpretations in accounting for stock awards to employees. Accordingly, no compensation expense is recognized in the Companys financial statements in connection with stock options granted to employees with exercise prices not less than fair market value. Deferred compensation for options granted to employees is determined as the difference between the deemed fair market value of the Companys common stock on the date options were granted and the exercise price. For purposes of the pro-forma disclosure, the estimated fair value of the options is assumed to be amortized to expense over the options vesting periods.
Pro forma information under SFAS 123 is as follows (in thousands, except per share data).
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, |
September 30, |
|||||||||||||||
| 2004 |
2003 |
2004 |
2003 |
|||||||||||||
Net income (loss): |
||||||||||||||||
As reported |
$ | 2,772 | $ | 652 | $ | 6,491 | $ | 1,983 | ||||||||
Add: Stock-based employee
compensation expense included in
reported net income |
| 15 | 7 | 38 | ||||||||||||
Deduct: Total stock-based
employee compensation expense
determined under fair value
method for all awards, net of
related tax effects |
(2,692 | ) | (4,261 | ) | (5,614 | ) | (11,316 | ) | ||||||||
Pro forma net income (loss) |
$ | 80 | $ | (3,594 | ) | $ | 884 | $ | (9,295 | ) | ||||||
Basic net income (loss) per share: |
||||||||||||||||
As reported |
$ | 0.09 | $ | 0.02 | $ | 0.20 | $ | 0.06 | ||||||||
Pro forma |
* | $ | (0.11 | ) | $ | 0.03 | $ | (0.30 | ) | |||||||
Diluted net income (loss) per share: |
||||||||||||||||
As reported |
$ | 0.08 | $ | 0.02 | $ | 0.19 | $ | 0.06 | ||||||||
Pro forma |
* | $ | (0.11 | ) | $ | 0.03 | $ | (0.30 | ) | |||||||
* Less than $0.01 per share
9
SYMYX TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:
| Stock Option Plans | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, |
September 30, |
|||||||||||||||
| 2004 |
2003 |
2004 |
2003 |
|||||||||||||
Expected dividend |
0.0 | % | 0.0 | % | 0.0 | % | 0.0 | % | ||||||||
Risk-free interest rate |
3.1 | % | 2.2 | % | 2.9 | % | 2.2 | % | ||||||||
Expected volatility |
61.0 | % | 68.0 | % | 61.0 | % | 68.0 | % | ||||||||
Expected life (in years) |
3.5 | 3.5 | 3.5 | 3.5 | ||||||||||||
The Black-Scholes option pricing model was developed for use in estimating the value of traded options that have no vesting restrictions and are fully transferable. In addition, option pricing models require the input of highly subjective assumptions including the expected stock price volatility. The Company uses projected data for expected volatility and expected life of its stock options based upon historical and other economic data trended into future years. Because the Companys employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the estimate, in managements opinion, the existing valuation models do not provide a reliable measure of the fair value of the Companys employee stock options. Under the Black-Scholes option pricing model, the weighted-average estimated fair values of employee stock options granted during the three and nine months ended September 30, 2004 were $9.47 and $11.12 per share, respectively, and for the three and nine months ended September 30, 2003 were $10.61 and $7.28 per share, respectively.
The fair value of shares of common stock relating to the Employee Stock Purchase Plan is estimated on the issuance date using the Black-Scholes model and the following weighted average assumptions for issuances made in 2004 and 2003: